Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
UP FRONT MATTERSScience in Renal Medicine
You have accessRestricted Access

PTH-Related Peptide (PTHrP) in Hypercalcemia

Gregory R. Mundy and James R. Edwards
JASN April 2008, 19 (4) 672-675; DOI: https://doi.org/10.1681/ASN.2007090981
Gregory R. Mundy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James R. Edwards
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

It is now 20 years since the tumor-associated factor parathyroid hormone–related peptide was identified. Since then, there have been significant changes in the understanding of the hypercalcemic syndromes associated with malignancy and with the role of this peptide in normal physiology as well as this specialized pathologic setting. Parathyroid hormone–related peptide has become a useful diagnostic tool in the differential diagnosis of hypercalcemia, and approaches to inhibit its expression or its effects by malignant cells hold promise for treating the hypercalcemia and osteolysis associated with some cancers.

Parathyroid hormone (PTH)-like factors responsible for the syndrome of hypercalcemia of malignancy were first proposed by Albright1 in the 1940s, on the basis of clinical observations in a single patient with hypercalcemia as a result of renal cell carcinoma. Albright suggested that the clinical syndrome in his patient resembled that of primary hyperparathyroidism, and the most likely explanation was that a PTH-like factor produced by the tumor was responsible. This thinking held sway for the next 40 yr, and with the identification of PTH and the development of antisera and immunoassays for its measurement in the 1960s and 1970s, many investigators searched for PTH in association with solid tumors. This search was by and large negative, other than for some confusion caused by the original antisera used for identification of PTH by RIA, and some investigators reported that PTH—or at least PTH-like molecules—were produced by tumors associated with malignancy.2–4 In retrospect, these assays may have been weakly recognizing PTH-related peptide (PTHrP), which is closely related at its N-terminal end to native PTH.

The situation was clarified further in the 1980s, when it was found that patients with hypercalcemia of malignancy frequently had increased nephrogenous cAMP and, moreover, had a circulating factor that increased adenylate cyclase activity in cultured bone cells or renal membranes in much the same manner that PTH did but was clearly not PTH.5,6 Thus, it was concluded that a PTH-like factor rather than native PTH was produced by tumors associated with hypercalcemia. In the late 1980s, the active principle responsible for this syndrome was identified as PTHrP, a peptide produced by tumors with close homology in the N-terminal sequence to PTH itself. In fact, PTHrP was found to have arisen after gene duplication of PTH, after which both gene products developed independently as two molecules with different structural complexities and mechanisms of control. Despite these differences, PTHrP exerts cellular affects through the binding and activation of the receptor that it shares with PTH, the type 1 PTH receptor.5,7–10

In the 1990s, further observations on PTHrP showed that it was produced not only by squamous cell carcinomas and other tumors associated with the syndrome of humoral hypercalcemia of malignancy but also by nonhypercalcemic tumors that caused local osteolysis, such as breast cancer,11,12 and in fact was responsible for the osteolysis associated with breast cancer in some models.13

After its identification and molecular cloning in the late 1980s, attention then turned to the physiologic role of PTHrP. Genetic mouse studies, by the mid-1990s widely used to characterize the physiologic roles of molecules in bone biology, showed that PTHrP was responsible for normal endochondral bone formation and controlled cartilage proliferation at the growth plate. Perichondral cells and chondrocytes synthesize PTHrP at the ends of the cartilage mold in the growth plate.14–16 PTHrP acts to prevent chondrocyte differentiation, thus delaying the appearance of postmitotic hypertrophic chondrocytes. PTHrP expression in the growth plate is controlled by Indian Hedgehog and its downstream mediators in the Gli family, through a negative feedback relationship. The Gs and Gg family of heterotrimeric G proteins mediates the effects of PTHrP on chondrocytes to limit their differentiation by the downstream cyclin-cdk inhibitor p57 that is suppressed to maintain chondrocyte proliferation and by the transcription factor Sox9.17–19 These effects of PTHrP at the growth plate seem to serve its major physiologic role.

PTHrP has been shown to play a local role in normal osteoblast function.20 Osteoblast-specific ablation of PTHrP in mice results in osteoporosis and an impairment of bone formation, suggesting a paracrine function. Thus, PTHrP may regulate normal osteoblast (and possibly osteoclast) differentiation and activity in the bone microenvironment,21 and PTHrP is being developed as a potential anabolic agent for osteoporosis with similar bone stimulatory effects to those of PTH.22,23 It also has other local cytokine-type roles of uncertain significance, including in the breast, urinary bladder, uterus, vascular smooth muscle, hair follicles, and skin. It also transfers calcium across the placenta from mother to fetus.24–26 Multiple fragments of PTHrP that have biologic activities have been described, but none of these has been confirmed as being important either physiologically or in vivo, and they still remain controversial and a matter of investigation.

With the observations that PTHrP plays an important role in both humoral hypercalcemia of malignancy and localized osteolysis associated with metastatic cancer, our concepts of the syndrome of hypercalcemia of malignancy have changed considerably. Up to the mid-1990s, it was thought that humoral hypercalcemia of malignancy was due to a circulating factor (namely PTHrP) and that localized osteolysis was due either to local cytokines or to direct effects of the tumor cells to cause localized bone destruction.27 With the observation that PTHrP may be responsible for both syndromes, at least in many patients, it has become clear that hypercalcemia of malignancy represents a spectrum, with PTHrP acting as the circulating factor when it is produced in excessive amounts by some tumors (and thereby causing humoral hypercalcemia) but under other circumstances acting as a local factor when produced by metastatic tumor cells in the bone microenvironment and causing osteolytic bone metastases (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Tumor syndromes associated with PTHrP production

Although PTHrP and PTH share the same receptor, there are differences between the syndromes of humoral hypercalcemia of malignancy and primary hyperparathyroidism. In humoral hypercalcemia of malignancy, bone formation is suppressed, and patients have a metabolic alkalosis rather than hyperchloremic acidosis. Moreover, serum 1,25 dihydroxyvitamin D3 concentrations are increased in primary hyperparathyroidism and suppressed in cancer. The reasons for these differences are unknown but may be due to other factors produced in conjunction with PTHrP in humoral hypercalcemia of malignancy.27,28

Other cancer syndromes are associated with PTHrP excess. Probably the most important of these is cachexia, which has been emphasized by Ogata and colleagues.29 Humoral hypercalcemia of malignancy induces accumulation of orixegenic peptides, such as neuropeptide Y in the arcuate nucleus of the hypothalamus, and both the cachexia and the mRNA for these peptides are reduced by anti-PTHrP therapies. It is still unclear whether cachexia is in fact due to PTHrP directly or is a consequence of increased tumor burden in the bone marrow.

Since PTHrP is such an important factor in causing these common syndromes associated with malignancy, different attempts have been made to block its biologic activity. One approach was the development of neutralizing antibodies to PTHrP, based on preclinical studies showing that neutralizing antibodies reduced serum calcium and decreased bone metastases in preclinical models.13,30 A second was to use small molecules that inhibit PTHrP transcription. We have identified specific small molecules that inhibit PTHrP transcription by tumor cells.31 These molecules, which are antimetabolites and include 6-thioguanine, were identified in a cell-based screening assay and found to reduce osteolysis and lower serum calcium in preclinical models of bone metastasis and hypercalcemia. A third was to develop antagonists of PTHrP binding to the PTH receptor, but this has not led to successful therapeutics so far. Other possibilities include small molecule approaches to inhibit PTHrP signal transduction within tumor cells.32

The regulation of PTHrP production by malignant cells is an issue of extreme interest. Why do certain cancer cells express a peptide that is physiologically important to cartilage cells of the growth plate? In the growth plate, PTHrP is regulated by the Hedgehog pathway and the Gli family of transcriptional mediators. We believe that similar mechanisms are also involved in cancer, albeit a little more complex. In solid tumors associated with PTHrP expression, it was found that PTHrP transcription is driven by Gli family members similar to what happens in the developing growth plate.33,34 The cancer cell uses this usually dormant developmental Hedgehog pathway that is important in embryonic life to enhance its expression of PTHrP, initiate bone resorption, and form a nidus for a bone metastasis. The process is driven by TGF-β, which is released into the bone microenvironment when bone is resorbed, because it is the most abundant growth factor in the bone matrix.35,36 This adds another level of understanding to the vicious cycle between tumor cells and osteoclasts in the bone microenvironment in metastatic cancer (Figure 1).27,37 Thus, TGF-β released as a consequence of bone resorption in the bone microenvironment stimulates expression of Gli family members in the Hedgehog pathway, in turn leading to increased PTHrP expression and bone resorption. The resorption of bone favors tumor cell growth and further release of active TGF-β from the bone matrix.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Pathologic roles of PTHrP. PTHrP is the principal factor in cancer-induced bone disease responsible for humoral hypercalcemia of malignancy and localized osteolysis. In the latter case, severe bone loss is initiated and fueled by the “vicious cycle,” whereby tumor-derived PTHrP stimulates osteoclastic resorption. The subsequent release of bone-derived growth factors stimulates tumor growth and PTHrP expression by tumor cells.

PTHrP is thus an extremely interesting molecule. Derived from the same ancestral gene as PTH, it has a limited physiologic role in embryonic and early postnatal life to regulate cartilage growth in developing long bones. It has no major physiologic role to our knowledge in adult life; however, it does have a major pathologic role, mediating bone destruction and hypercalcemia by certain tumors that have learned to activate the developmental Hedgehog pathway and express PTHrP, which allows the tumor cells to create a “safe harbor” in the form of a bone metastasis. As our knowledge of this interesting process by which cancer destroys bone grows, it seems certain that successful pharmacologic attempts to limit the expression of PTHrP or its effects hold potential benefits for the multitude of patients with advanced cancer.

Disclosures

None.

Acknowledgments

Our work in this area is supported by grants CA-40035, CA-114000, and U54–126505 from the National Institutes of Health.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • © 2008 American Society of Nephrology

References

  1. ↵
    Albright F: Case records of the Massachusetts General Hospital: Case 39061. N Engl J Med 225 : 789 –796, 1941
    OpenUrlCrossRef
  2. ↵
    Simpson EL, Mundy GR, D'Souza SM, Ibbotson KJ, Bockman R, Jacobs JW: Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. N Engl J Med 309 : 325 –330, 1983
    OpenUrlPubMed
  3. Benson RC Jr, Riggs BL, Pickard BM, Arnaud CD: Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. Am J Med 56 : 821 –826, 1974
    OpenUrlCrossRefPubMed
  4. ↵
    Sherwood LM, O'Riordan JL, Aurbach GD, Potts JT Jr: Production of parathyroid hormone by nonparathyroid tumors. J Clin Endocrinol Metab 27 : 140 –146, 1967
    OpenUrlCrossRefPubMed
  5. ↵
    Stewart AF, Wu T, Goumas D, Burtis WJ, Broadus AE: N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: Identification of parathyroid hormone-like and parathyroid hormone-unlike domains. Biochem Biophys Res Commun 146 : 672 –678, 1987
    OpenUrlCrossRefPubMed
  6. ↵
    Rodan SB, Noda M, Wesolowski G, Rosenblatt M, Rodan GA: Comparison of postreceptor effects of 1-34 human hypercalcemia factor and 1-34 human parathyroid hormone in rat osteosarcoma cells. J Clin Invest 81 : 924 –927, 1988
    OpenUrlCrossRefPubMed
  7. ↵
    Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, et al.: Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A 84 : 5048 –5052, 1987
    OpenUrlAbstract/FREE Full Text
  8. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, Rosenblatt M, Nissenson RA: Parathyroid hormonelike protein from human renal carcinoma cells: Structural and functional homology with parathyroid hormone. J Clin Invest 80 : 1803 –1807, 1987
    OpenUrlCrossRefPubMed
  9. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, et al.: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237 : 893 –896, 1987
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart AF: Humoral hypercalcemia of cancer: Identification of a novel parathyroid hormone-like peptide. N Engl J Med 319 : 556 –563, 1988
    OpenUrlCrossRefPubMed
  11. ↵
    Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ: Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res 51 : 3059 –3061, 1991
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, Bennett RC, Martin TJ: Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res 50 : 7710 –7716, 1990
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98 : 1544 –1549, 1996
    OpenUrlCrossRefPubMed
  14. ↵
    Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg HM, Mulligan RC: Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8 : 277 –289, 1994
    OpenUrlAbstract/FREE Full Text
  15. Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, Karperien M, Defize LH, Ho C, Mulligan RC, Abou-Samra AB, Juppner H, Segre GV, Kronenberg HM: PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273 : 663 –666, 1996
    OpenUrlAbstract
  16. ↵
    Kronenberg HM, Lee K, Lanske B, Segre GV: Parathyroid hormone-related protein and Indian hedgehog control the pace of cartilage differentiation. J Endocrinol 154[Suppl] : S39 –S45, 1997
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr, Kronenberg HM, et al.: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254 : 1024 –1026, 1991
    OpenUrlAbstract/FREE Full Text
  18. Huang W, Chung UI, Kronenberg HM, de Crombrugghe B: The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones. Proc Natl Acad Sci U S A 98 : 160 –165, 2001
    OpenUrlAbstract/FREE Full Text
  19. ↵
    MacLean HE, Guo J, Knight MC, Zhang P, Cobrinik D, Kronenberg HM: The cyclin-dependent kinase inhibitor p57(Kip2) mediates proliferative actions of PTHrP in chondro-cytes. J Clin Invest 113 : 1334 –1343, 2004
    OpenUrlCrossRefPubMed
  20. ↵
    Miao D, He B, Jiang Y, Kobayashi T, Soroceanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC: Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34. J Clin Invest 115 : 2402 –2411, 2005
    OpenUrlCrossRefPubMed
  21. ↵
    Martin TJ: Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 115 : 2322 –2324, 2005
    OpenUrlCrossRefPubMed
  22. ↵
    Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF: Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88 : 569 –575, 2003
    OpenUrlCrossRefPubMed
  23. ↵
    Horwitz MJ, Tedesco MB, Sereika SM, Garcia-Ocana A, Bisello A, Hollis BW, Gundberg C, Stewart AF: Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: A dose escalation study. Osteoporos Int 17 : 225 –230, 2006
    OpenUrlCrossRefPubMed
  24. ↵
    Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF: Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76 : 127 –173, 1996
    OpenUrlPubMed
  25. Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, Broadus AE: Rescue of the parathyroid hormone-related pro-tein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development 125 : 1285 –1294, 1998
    OpenUrlAbstract
  26. ↵
    Rodda CP, Kubota M, Heath JA, Ebeling PR, Moseley JM, Care AD, Caple IW, Martin TJ: Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: Comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy. J Endocrinol 117 : 261 –271, 1988
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Guise TA, Mundy GR: Cancer and bone. Endocr Rev 19 : 18 –54, 1998
    OpenUrlCrossRefPubMed
  28. ↵
    Mundy GR, Guise TA: Hypercalcemia of malignancy. Am J Med 103 : 134 –145, 1997
    OpenUrlCrossRefPubMed
  29. ↵
    Hashimoto H, Azuma Y, Kawasaki M, Fujihara H, Onuma E, Yamada-Okabe H, Takuwa Y, Ogata E, Ueta Y: Parathyroid hormone-related protein induces cachectic syndromes without directly modulating the expression of hypothalamic feeding-regulating peptides. Clin Cancer Res 13 : 292 –298, 2007
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Kukreja SC, Shevrin DH, Wimbiscus SA, Ebeling PR, Danks JA, Rodda CP, Wood WI, Martin TJ: Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. J Clin Invest 82 : 1798 –1802, 1988
    OpenUrlPubMed
  31. ↵
    Gallwitz WE, Guise TA, Mundy GR: Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest 110 : 1559 –1572, 2002
    OpenUrlCrossRefPubMed
  32. ↵
    Kakonen SM, Mundy GR: Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97 : 834 –839, 2003
    OpenUrlCrossRefPubMed
  33. ↵
    Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, Story B, Zhao M, Mundy GR: The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 66 : 7548 –7553, 2006
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Miao D, Liu H, Plut P, Niu M, Huo R, Goltzman D, Henderson JE: Impaired endochondral bone development and osteopenia in Gli2-deficient mice. Exp Cell Res 294 : 210 –222, 2004
    OpenUrlCrossRefPubMed
  35. ↵
    Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M: Growth factors in bone matrix: Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261 : 12665 –12674, 1986
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103 : 197 –206, 1999
    OpenUrlCrossRefPubMed
  37. ↵
    Mundy GR: Mechanisms of bone metastasis. Cancer 80 : 1546 –1556, 1997
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 19 (4)
Journal of the American Society of Nephrology
Vol. 19, Issue 4
April 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
PTH-Related Peptide (PTHrP) in Hypercalcemia
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
PTH-Related Peptide (PTHrP) in Hypercalcemia
Gregory R. Mundy, James R. Edwards
JASN Apr 2008, 19 (4) 672-675; DOI: 10.1681/ASN.2007090981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
PTH-Related Peptide (PTHrP) in Hypercalcemia
Gregory R. Mundy, James R. Edwards
JASN Apr 2008, 19 (4) 672-675; DOI: 10.1681/ASN.2007090981
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

UP FRONT MATTERS

  • Molecular Characterization of Membranous Nephropathy: Quo Vadis?
  • More than a Marker: Arginase-1 in Kidney Repair
  • Enabling Patient Choice: The “Deciding Not to Decide” Option for Older Adults Facing Dialysis Decisions
Show more UP FRONT MATTERS

Science in Renal Medicine

  • Regulatory T Cells in AKI
  • Defining the Signals that Constitute the Nephron Progenitor Niche
  • Mechanisms of Hypoxia Responses in Renal Tissue
Show more Science in Renal Medicine

Cited By...

  • Hypercalcaemia due to ovarian small cell carcinoma of the hypercalcaemic type
  • Confusion and hypercalcemia in an 80-year-old man
  • Identification of PTHrP(12-48) as a Plasma Biomarker Associated with Breast Cancer Bone Metastasis
  • TGF-{beta} Promotion of Gli2-Induced Expression of Parathyroid Hormone-Related Protein, an Important Osteolytic Factor in Bone Metastasis, Is Independent of Canonical Hedgehog Signaling
  • Parathyroid Hormone-related Peptide Regulates Matrix Metalloproteinase-13 Gene Expression in Bone Metastatic Breast Cancer Cells
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire